NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...

The test was previously covered for use in colorectal cancer patients in the early post-surgical setting only.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

Highlights from the first day included updates from several firms about their China businesses and M&A strategies.

Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...

The proteomic blood test could be a noninvasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

NEW YORK – A University of Michigan lab has developed a blood-based test to detect recurrence of human papilloma virus-positive head and neck cancer sooner than standard-of-care imaging and clinical ...

The Dublin-based firm said that it will use the money for development for its rapid test to aid the diagnosis and treatment of sepsis.

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...